Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists.

Purpose: This study reports and analyzes the findings from the responses of 192 neurologists in the United States and Canada to a new survey instrument distributed in April 2020 to assess NMO practice and prescribing changes during the Covid19 pandemic.

Principal Results: 92% of responding neurologists considered their NMO patients to be at an elevated risk of acquiring Covid19. They also indicated sharp declines in visits, delays in treatment and related services, and several unmet needs deterring treatment.

Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.

Objective: To report the understanding and decision-making of neuroimmunologists and their treatment of patients with multiple sclerosis (MS) during the early stages of the SARS-CoV-2 (COVID-19) outbreak.

Methods: A survey instrument was designed and distributed online to neurologists in April 2020.

Results: There were 250 respondents (response rate 21.

Neuromyelitis optica testing and treatment: Availability and affordability in 60 countries.

Background: We characterize the variations in availability and affordability of NMO diagnostic testing and treatment by geographic region and country-level income group.

Methods: A structured survey was distributed in English, French, and Spanish in late 2018 to neurologists and other physicians who encounter NMO patients.

Results: Respondents (response rate 45%, 64/143 countries contacted) came from all WHO world regions and World Bank country income levels (49% university-based; 13 low-, 16 lower middle-, 16 upper-middle-, and 15 high-income countries).